CR represents an early index of potential long survival in multiple myeloma.

abstract：:ABO incompatibility is not considered a contraindication for allogeneic haematopoietic stem cell transplantation (HSCT) despite its association with several immunohaematological complications. At present, there is no general agreement concerning the best methods to reduce these problems. To survey current practice rel...

journal_title：Bone marrow transplantation

authors： Raimondi R,Soli M,Lamparelli T,Bacigalupo A,Arcese W,Belloni M,Rodeghiero F,Gruppo Italiano Trapianto di Midolla Osseo.

更新日期：2004-08-01 00:00:00

abstract：:PBSCs are usually mobilized using G-CSF with or without chemotherapy. With the emergence of newer mobilizing agents, predicting poor mobilization may allow early intervention and prevent the costs and complications associated with remobilization. We retrospectively evaluated a cohort of 1556 patients seen between Janu...

journal_title：Bone marrow transplantation

authors： Sinha S,Gastineau D,Micallef I,Hogan W,Ansell S,Buadi F,Dingli D,Dispenzieri A,Gertz M,Greiner C,Hayman S,Inwards D,Johnston P,Lacy M,Litzow M,Porrata L,Winters JL,Kumar S

更新日期：2011-07-01 00:00:00

abstract：:Identifying risk factors that lead to graft failure may reduce morbidity and mortality after bone marrow transplantation (BMT) for hematologic malignancies. We evaluated engraftment of all patients with acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and myelodysplastic syndrome (MDS) receiving an...

journal_title：Bone marrow transplantation

authors： Schultz KR,Ratanatharathorn V,Abella E,Eisenbrey AB,Karanes C,Lum LG,de Planque MM,Uberti JP,Ravindranath Y,Sensenbrenner LL

更新日期：1994-06-01 00:00:00

abstract：:Cord blood transplantation, which has lower risk of graft-versus-host disease than bone marrow transplantation, might have higher risk of infections. A system to quantify four herpesviruses, CMV, human herpesvirus 6 (HHV6), EBV, varicella-zoster virus using the real-time PCR assay was established and applied for prosp...

journal_title：Bone marrow transplantation

authors： Tanaka N,Kimura H,Hoshino Y,Kato K,Yoshikawa T,Asano Y,Horibe K,Kojima S,Morishima T

更新日期：2000-12-01 00:00:00

abstract：:The cellular immunoincompetence which follows bone marrow transplantation (BMT) allows both primary and reactivation infection with herpes viruses. We report the overall incidence and timing of varicella zoster virus (VZV) infections after BMT, including the clinical course, complications and associated clinical risk ...

journal_title：Bone marrow transplantation

authors： Han CS,Miller W,Haake R,Weisdorf D

更新日期：1994-03-01 00:00:00

abstract：:From 1983 to 1994 two types of trials were performed. Between 1983 and 1987 a modified VAPA protocol (post-remission therapy with intensive sequential blocks for 12-16 months) was given to 40 patients from two institutions. CR was attained in 75% and 5-year EFS was 35%. In 1988 a post-remission protocol based on inten...

journal_title：Bone marrow transplantation

authors： Ortega JJ,Olivé T,Díaz de Heredia C,Coll MT,Bastida P,Massuet L

更新日期：1996-11-01 00:00:00

abstract：:Certain leukemias have a high relapse risk even after allo-SCT, and GVHD prophylaxis with calcineurin inhibitors (CNIs) may interfere with a possible GVL effect. Therefore, we replaced CYA by sirolimus in patients with high relapse risk. In contrast to CNIs, sirolimus promotes the generation of regulatory T-cells and ...

journal_title：Bone marrow transplantation

authors： Schleuning M,Judith D,Jedlickova Z,Stübig T,Heshmat M,Baurmann H,Schwerdtfeger R

更新日期：2009-05-01 00:00:00

abstract：:We report the results of a retrospective analysis in 27 pediatric patients who received low-dose MTX as the second-line treatment for steroid-refractory or -dependent acute and chronic GVHD. Between July 2000 and May 2006, 10 patients with aGVHD and 17 with cGVHD were treated with MTX at a dose of 3-10 mg/m(2) weekly....

journal_title：Bone marrow transplantation

authors： Inagaki J,Nagatoshi Y,Hatano M,Isomura N,Sakiyama M,Okamura J

更新日期：2008-03-01 00:00:00

abstract：:The effectiveness of an antibody-enzyme immunotoxin (eIT) was investigated on human T cells. This enzyme immunotoxin contained glucose oxidase (GO) and lactoperoxidase (LPO) chemically coupled to the pan-leukocyte-specific mouse monoclonal antibody (MoAb) 097 (097-GO and 097-LPO). Human peripheral blood mononuclear ce...

journal_title：Bone marrow transplantation

authors： Ito HO,Morizet J,Coulombel L,Goavec M,Rousseau V,Bernard A,Stanislawski M

更新日期：1989-09-01 00:00:00

abstract：:Neutropenia following high-dose chemotherapy leads to a high incidence of infectious complications, of which central venous catheter-related infections predominate. Catheter-related infections and associated risk factors in 392 patients participating in a randomized adjuvant breast cancer trial and assigned to receive...

journal_title：Bone marrow transplantation

authors： Nieboer P,de Vries EG,Mulder NH,Rodenhuis S,Bontenbal M,van der Wall E,van Hoesel QG,Smit WM,Hupperets P,Voest EE,Nooij MA,Boezen HM,van der Graaf WT

更新日期：2008-10-01 00:00:00

abstract：:Prognostic factors for survival following allogeneic BMT for AML include age, disease status and cytogenetic risk classification. Lactate dehydrogenase (LDH) levels have not been studied as a potential risk factor. We reviewed our experience with BMT for AML and included LDH at the time of admission in an analysis of ...

journal_title：Bone marrow transplantation

authors： Kalaycio M,Rybicki L,Pohlman B,Dean R,Sweetenham J,Andresen S,Sobecks R,Sekeres MA,Advani A,Brown S,Bolwell B

更新日期：2007-10-01 00:00:00

abstract：:Allogeneic hematopoietic stem cell transplantation (HSCT) in first complete remission is a standard of care for adult patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) and high risk of relapse. However, the stratification systems vary among study groups. Inadequate response at the ...

journal_title：Bone marrow transplantation

authors： Giebel S,Marks DI,Boissel N,Baron F,Chiaretti S,Ciceri F,Cornelissen JJ,Doubek M,Esteve J,Fielding A,Foa R,Gorin NC,Gökbuget N,Hallböök H,Hoelzer D,Paravichnikova E,Ribera JM,Savani B,Rijneveld AW,Schmid C,Wartiov

更新日期：2019-06-01 00:00:00

abstract：:We sent a questionnaire to 22 teams performing allogeneic and autologous bone marrow transplants (BMT) in the UK enquiring about routine use of prophylactic antimicrobials post-transplant, use of CMV-negative blood products and the incidence of major infection acquired more than 3 months post-BMT. Eighteen centres (82...

journal_title：Bone marrow transplantation

authors： Hoyle C,Goldman JM

更新日期：1994-08-01 00:00:00

abstract：:To examine the effect of granulocyte colony-stimulating factor (G-CSF) on hematopoietic recovery after high-dose chemotherapy and peripheral blood progenitor cell transplantation (PBPCT), 20 patients with hematologic malignancies were divided into two groups. One group was given G-CSF at a daily dose of 50 micrograms/...

journal_title：Bone marrow transplantation

authors： Shimazaki C,Oku N,Uchiyama H,Yamagata N,Tatsumi T,Hirata T,Ashihara E,Okawa K,Goto H,Inaba T

更新日期：1994-03-01 00:00:00

abstract：:High-dose carboplatin, etoposide and ifosfamide (CEI) is an active chemotherapy regimen (HDCT) in solid tumors and lymphomas. In patients with previous exposure to cisplatin, its nephrotoxicity is dose-limiting. To determine the implications of nephrotoxicity on hematological recovery and clinical outcome, we analyzed...

journal_title：Bone marrow transplantation

authors： Beyer J,Rick O,Weinknecht S,Kingreen D,Lenz K,Siegert W

更新日期：1997-11-01 00:00:00

abstract：:There is substantial progress in preventing and treating cytomegalovirus (CMV) infections and CMV-related disease after allogeneic bone marrow transplantation. In CMV-seronegative recipients, use of CMV-seronegative blood products eliminates most CMV infections. Effective prophylaxis for CMV-seropositive recipients is...

journal_title：Bone marrow transplantation

authors： Winston DJ,Gale RP

更新日期：1991-07-01 00:00:00

abstract：:A 55-year-old man with acute myeloid leukemia in second relapse presented 4 months after haploidentical CD34+-selected hematopoietic stem cell transplantation (HSCT) with symmetric, progressive neurological deficits of the lower extremities. Although there was no molecular evidence for drug resistance in the cerebral-...

journal_title：Bone marrow transplantation

authors： Zeiser R,Grüllich C,Bertz H,Pantazis G,Hufert FT,Bley TA,Finke J

更新日期：2004-01-01 00:00:00

abstract：:Malignant osteopetrosis (MOP) is an autosomal recessive disease in which osteoclast dysfunction results in excessive bone deposition and early infant death. Thirteen children suffering from MOP from four related families all belonging to one Bedouin tribe, were studied. The disease was diagnosed as early as at a few d...

journal_title：Bone marrow transplantation

authors： Kapelushnik J,Shalev C,Yaniv I,Aker M,Carmi R,Cohen Z,Mozer A,Schulman C,Stein G,Or R

更新日期：2001-01-01 00:00:00

abstract：:The aim was to evaluate two transplant strategies for patients who lack HLA-identical donors, namely HLA-A, HLA-B or -DR beta 1 mismatched unrelated donor (MM URD) transplants (n=14) and umbilical cord blood transplants (UCB, n=27). Diagnosis, disease stage and age were similar in the two groups. Cell dose was lower i...

journal_title：Bone marrow transplantation

authors： Ringdén O,Okas M,Uhlin M,Uzunel M,Remberger M,Mattsson J

更新日期：2008-11-01 00:00:00

abstract：:Relapse is a serious complication following high-dose therapy and autologous bone marrow transplantation (ABMT) for malignant lymphoma (ML). Allogeneic transplantation (alloSCT) is a therapeutic option. However, it is associated with a high incidence of transplant-related organ toxicity and mortality. We recently repo...

journal_title：Bone marrow transplantation

authors： Nagler A,Slavin S,Varadi G,Naparstek E,Samuel S,Or R

更新日期：2000-05-01 00:00:00

abstract：:On August 30, 2017, the U.S. Food and Drug Administration (US-FDA) approved tisagenlecleucel (KYMRIAH, Novartis, Basel, Switzerland), a synthetic bioimmune product of anti-CD19 chimeric antigen receptor-T cells (CAR-T), for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic ...

journal_title：Bone marrow transplantation

authors： Kansagra AJ,Frey NV,Bar M,Laetsch TW,Carpenter PA,Savani BN,Heslop HE,Bollard CM,Komanduri KV,Gastineau DA,Chabannon C,Perales MA,Hudecek M,Aljurf M,Andritsos L,Barrett JA,Bachanova V,Bonini C,Ghobadi A,Gill SI,Hi

更新日期：2019-11-01 00:00:00

abstract：:Recent reports have suggested that the total number of autologous or allogeneic hematopoietic stem cell (HSC) infused after high-dose chemotherapy might predict survival, post-transplant morbidity and rate of hematopoietic engraftment. However, HSC capable of long-term multilineage potential are still poorly defined, ...

journal_title：Bone marrow transplantation

authors： Bertolini F,Battaglia M,Lanza A,Gibelli N,Palermo B,Pavesi L,Robustelli della Cuna G

更新日期：1998-07-01 00:00:00

abstract：:Stroke is an important complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Nevertheless, few studies have been published to analyzed the occurrence and prognosis of stroke after allo-HSCT. From January 2007 to December 2018 in Peking University People's Hospital, 6449 patients receiv...

journal_title：Bone marrow transplantation

authors： Cai X,Fu HX,Mo XD,Wang Y,Zhang YY,Wu J,Han W,Tang FF,Gui RY,Chen H,Chen Y,Zhao P,Yan CH,Wang JZ,Chen YH,Chang YJ,Xu LP,Liu KY,Huang XJ,Zhang XH

更新日期：2020-11-01 00:00:00

abstract：:Twenty-nine pediatric allogeneic bone marrow transplant (BMT) recipients, ages 2-17 years, were followed prospectively for cytomegalovirus (CMV) infection. Patients at risk received ganciclovir (GCV) prophylactically at a dose of 5 mg/kg/day i.v., 3 to 5 days per week, until day 100. Surveillance blood and urines were...

journal_title：Bone marrow transplantation

authors： Canpolat C,Culbert S,Gardner M,Whimbey E,Tarrand J,Chan KW

更新日期：1996-04-01 00:00:00

abstract：:beta-Thalassemia major and sickle cell disease (SCD) are among the most common hereditary disorders worldwide. The supportive treatment of beta-thalassemia major requires chronic, life-long RBC transfusions, which cause progressive iron overload and the potential for impaired endocrine, cardiac and hepatic function. T...

journal_title：Bone marrow transplantation

authors： Bhatia M,Walters MC

更新日期：2008-01-01 00:00:00

abstract：:This retrospective study from the Italian Association of Pediatric Hematology Oncology-Bone Marrow Transplant Group (AIEOP-TMO) reports the results of consolidation with high-dose melphalan and autologous hematopoietic stem cell transplantation (auto-HSCT) in patients with acute myeloid leukemia (AML) in first complet...

journal_title：Bone marrow transplantation

authors： Cesaro S,Meloni G,Messina C,Pillon M,Proglia A,Lanino E,Caniggia M,Bagnulo S,Pession A,Locatelli F,Italian Pediatric Group for Bone Marrow Transplantation.

更新日期：2001-07-01 00:00:00

abstract：:Infections are a major cause of morbidity and mortality in patients undergoing high-dose therapy and subsequent autologous or allogeneic haemopoietic stem cell transplantation, despite the change from topical to systemic anti-infection prophylaxis and the introduction of growth factors and new antimicrobial drugs. We ...

journal_title：Bone marrow transplantation

authors： Krüger W,Rüssmann B,Kröger N,Salomon C,Ekopf N,Elsner HA,Kaulfers PM,Mack D,Fuchs N,Dürken M,Kabisch H,Erttmann R,Zander AR

更新日期：1999-03-01 00:00:00

abstract：:Blood concentrations of cyclosporine A (CsA) >or=800 microg/l measured 2 h post-dosing, the C2 concentration, is necessary to obtain a maximal pharmacological effect and correlates well with transplant-related complications such as transplant rejection and toxicity. In an open crossover study CsA blood levels were mea...

journal_title：Bone marrow transplantation

authors： Hendriks MP,Blijlevens NM,Schattenberg AV,Burger DM,Donnelly JP

更新日期：2006-10-01 00:00:00

abstract：:Allogeneic hematopoietic stem cell transplantation (SCT) from unaffected donors remains the only modality for the correction of hematological abnormalities in Fanconi anemia (FA) patients. We performed four HLA-matched related donor SCT using a novel irradiation and cyclophosphamide-free conditioning regimen. The prot...

journal_title：Bone marrow transplantation

authors： Maschan AA,Trakhtman PE,Balashov DN,Shipicina IP,Skorobogatova EV,Skvortsova YV,Dyshlevaja ZM,Samochatova EV,Rumiantsev AG

更新日期：2004-08-01 00:00:00

abstract：:While bone marrow (BM) grafts were initially used for T-replete HLA-haploidentical related donors transplantation (Haplo-SCT) with post-transplantation cyclophosphamide (PT-Cy), the use of peripheral blood stem cell (PBSC) remains debated. We thus conducted a detailed analysis evaluating the incidence, risk factors, a...

journal_title：Bone marrow transplantation

authors： Granata A,Fürst S,Bramanti S,Legrand F,Sarina B,Harbi S,De Philippis C,Faucher C,Chabannon C,Lemarie C,Calmels B,Mariotti J,Maisano V,Weiller PJ,Mokart D,Vey N,Bouabdallah R,Castagna L,Blaise D,Devillier R

更新日期：2019-11-01 00:00:00